XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
Presentation to Discuss Novel Findings on MABp1 in the Prevention of Coronary Thrombosis
AUSTIN, Texas, Nov. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that research involving MABp1, the company's IL-1 alpha (IL-1[alpha]) antibody, will be featured in an oral presentation during the American Heart Association Scientific Sessions being held November 11-15 in Anaheim, California. The presentation will provide evidence that IL-1[alpha] is associated with Neutrophil Extracellular Traps (NETs) and is involved in endothelial activation and thrombogenesis.
|Title:||Neutrophil Extracellular Traps Increase Endothelial Activation and Thrombogenicity via IL-1[alpha] and NF-[kappa]B: Implications for Superficial Erosion|
|Session:||Endothelial Dysfunction in Vascular Disease|
|Date:||Monday, November 13, 2017|
|Time:||5:45 p.m. - 5:55 p.m. (Pacific Time)|
|Location:||Anaheim Convention Center, Anaheim, CA|
About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Appian Corporation23.5.2018 13:31 | pressemeddelelse
Addiko Bank Implements Digital Banking Solutions on Appian
VITEC23.5.2018 10:01 | pressemeddelelse
VITEC to Showcase High-Quality, Low-Bandwidth Tactical Video Solutions at Eurosatory 2018
Jobindex A/S23.5.2018 08:33 | pressemeddelelse
1. kvartal 2018: Jobindex er kommet godt fra start
Gallene Sciences PVT. LTD22.5.2018 23:02 | pressemeddelelse
MyoGen: Leaders of an Anabolic Revolution
XBiotech, Inc22.5.2018 14:01 | pressemeddelelse
XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
PubMatic, Inc.22.5.2018 14:01 | pressemeddelelse
Apps Lead the Charge as Mobile Advertising Continues to Grow Worldwide
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum